Compare Eos Energy Enterprises Inc (EOSE) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eos Energy Enterprises Inc vs Viatris Inc — how do they compare? Eos Energy Enterprises Inc trades at $4.21 (market cap $1.54B), while Viatris Inc trades at $16.21 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 12.1× Eos Energy Enterprises Inc's market cap, and Viatris Inc pays a 2.95% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals.
| EOSE | VTRS | |
|---|---|---|
Market Cap | $1.54B | $18.69B |
Sector | Energy | Health |
52-Week High | $19.19 | $17.86 |
52-Week Low | $3.14 | $9.49 |
Enterprise Value | $1.88B | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $4.38, up 8.15% on the day, amid mixed technical signals and persistent fundamental challenges. The company reported a Q2 2026 loss of $1.20 per share, missing estimates, but revenue growth is accelerating, with 2026 revenue projected at $214 million. Negative profit margins and cash burn remain significant concerns, though analyst sentiment shows a mixed but cautious outlook with a consensus price target of $7.75.
The stock presents a high-risk opportunity driven by revenue growth potential in energy storage, but investors face substantial risks from continued losses, dilution, and competitive pressures. Upside depends on execution improving margins and achieving profitability, while downside risks include further earnings misses and liquidity challenges.
Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.
Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eos Energy Enterprises Inc
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
